Lexicon Pharmaceuticals | LXRX - Current Liabilities


Lexicon Pharmaceuticals reported $9.9M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Illumina USD 1.57B 19M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
J&J USD 54.9B 2.82B Jun/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
MannKind USD 134.56M 36.47M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Moderna USD 2.4B 408M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Thermo Fisher Scientific USD 15.07B 448M Jun/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025